Cathay Biotech's (SHSE:688065) Anemic Earnings Might Be Worse Than You Think
Cathay Biotech's (SHSE:688065) Anemic Earnings Might Be Worse Than You Think
Cathay Biotech Inc.'s (SHSE:688065) recent weak earnings report didn't cause a big stock movement. However, we believe that investors should be aware of some underlying factors which may be of concern.
广东省华宇生物科技股份有限公司(SHSE:688065)最近弱势的财报并没有引起股价大幅波动。然而,我们认为投资者应该注意一些潜在的因素,这可能是令人担忧的。
The Impact Of Unusual Items On Profit
除了稀释之外,还应该注意的是,万集科技在过去12个月中因不寻常项目获得了价值人民币3.5万元的利润。虽然我们希望看到利润增加,但当这些不寻常项目对利润做出重大贡献时,我们会更加谨慎。我们对全球大部分上市公司的数据进行了分析,发现不寻常项目往往是一次性的。这正如我们所期望的那样,因为这些提升被描述为"不寻常"。相对于其利润而言,万集科技在2021年12月前的不寻常项目贡献大。因此,我们可以推断出,这些不寻常项目正在使其财务利润显著增强。
Importantly, our data indicates that Cathay Biotech's profit received a boost of CN¥80m in unusual items, over the last year. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. Which is hardly surprising, given the name. Cathay Biotech had a rather significant contribution from unusual items relative to its profit to June 2024. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.
重要的是,我们的数据显示,广东省华宇生物科技去年在非常规项目中获得了8000万人民币的推动。尽管有更高的利润总是令人愉快的,但非常规项目的大额贡献有时会削弱我们的热情。当我们对成千上万家上市公司进行数据分析时,我们发现,在某一年中由非常规项目带来的推动往往不会在下一年再次发生。这并不奇怪,因为名字里就有“非常规”。与2024年6月相比,广东省华宇生物科技的非常规项目贡献相对较大。其他条件相等的情况下,这可能会导致法定利润对潜在盈利能力的指导不足。
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Cathay Biotech.
注意:我们始终建议投资者检查资产负债表的强度。单击此处查看我们对广东省华宇生物科技的资产负债表分析。
Our Take On Cathay Biotech's Profit Performance
我们对广东省华宇生物科技的盈利表现的见解
As we discussed above, we think the significant positive unusual item makes Cathay Biotech's earnings a poor guide to its underlying profitability. As a result, we think it may well be the case that Cathay Biotech's underlying earnings power is lower than its statutory profit. Sadly, its EPS was down over the last twelve months. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. To that end, you should learn about the 2 warning signs we've spotted with Cathay Biotech (including 1 which is a bit concerning).
正如我们上面所讨论的,我们认为突出的正常额外项目使得国泰生物的收益成为对其潜在盈利能力的不良指引。因此,我们认为国泰生物的潜在盈利能力很可能低于其法定利润。遗憾的是,其每股收益在过去十二个月内出现下滑。当分析其收益时,我们只是皮毛触及,您还可以考虑利润率、预测增长、投资回报率等其他因素。考虑到这一点,如果您想对该公司进行更多分析,了解所涉风险是至关重要的。为此,您应该了解我们在国泰生物发现的2个警示信号(其中有1个值得关注)。
This note has only looked at a single factor that sheds light on the nature of Cathay Biotech's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
本注仅关注一项能揭示国泰生物利润性质的因素。但还有许多其他方式来了解公司的情况。一些人认为高净资产收益率是优质业务的良好迹象。虽然这可能需要您进行一些研究,但您可能会发现这个自由收集了高净资产收益率公司的收藏,或者 这份拥有重要内部持股的股票列表是有用的。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。